• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

    7/26/23 9:34:55 PM ET
    $GRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRNA alert in real time by email
    SC 13D/A 1 d536894dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    GreenLight Biosciences Holdings, PBC

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    39536G 105

    (CUSIP Number)

    David Furneaux

    Kodiak Ventures Management Company, Inc.

    11 Peter Grover Rd

    Bethel, ME 04217

    617-901-8590

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 24, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 39536G 105    13D    Page 2 of 7 pages

     

      1    

      Names of Reporting Persons

     

      Kodiak Venture Partners III, L.P.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)   ☐         (b)   ☒(1)

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      0

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      0

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      0% (2)

    14  

      Type of Reporting Person

     

      PN


    CUSIP No. 39536G 105    13D    Page 3 of 7 pages

     

      1    

      Names of Reporting Persons

     

      Kodiak III Entrepreneurs Fund, L.P.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒(1)

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      0

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      0

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      0% (3)

    14  

      Type of Reporting Person

     

      PN


    CUSIP No. 39536G 105    13D    Page 4 of 7 pages

     

      1    

      Names of Reporting Persons

     

      Kodiak Ventures Management III, L.P. (2)

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒(1)

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      0

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      0

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      0% (3)

    14  

      Type of Reporting Person

     

      PN

     


    CUSIP No. 39536G 105    13D    Page 5 of 7 pages

     

      1    

      Names of Reporting Persons

     

      Kodiak Ventures Management (GP), LLC (2)

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒(1)

     

      3  

      SEC Use Only

     

      4  

      Source of Funds (See Instructions)

     

      OO

      5  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

      ☐

      6  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      Sole Voting Power

     

      0

         8   

      Shared Voting Power

     

      0

         9   

      Sole Dispositive Power

     

      0

       10   

      Shared Dispositive Power

     

      0

    11    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    12  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13  

      Percent of Class Represented by Amount in Row (11)

     

      0% (3)

    14  

      Type of Reporting Person

     

      PN

     

    (1)

    This Schedule 13D/A is filed by Kodiak Venture Partners III, L.P. (“Kodiak III”), Kodiak III Entrepreneurs Fund, L.P. (“Kodiak III-E”), Kodiak Ventures Management III, L.P. (“Kodiak III GP”), and Kodiak Ventures Management (GP), LLC (“Kodiak GP-GP” and, with Kodiak III, Kodiak III-E and Kodiak III GP, collectively, the “Reporting Persons”).

    (2)

    Kodiak III GP serves as the sole general partner of each of Kodiak III and Kodiak III-E, and Kodiak GP-GP serves as the sole general partner of Kodiak III GP and, as such, Kodiak GP-GP possesses voting and dispositive power over any securities held by Kodiak III and Kodiak III-E.


    CUSIP No. 39536G 105    13D    Page 6 of 7 pages

     

    Explanatory Note

    This Amendment No. 2 (this “Amendment No. 2”) to this Statement on Schedule 13D amends and supplements the Statement on Schedule 13D (the “Statement”) previously filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on February 11, 2022 and the Amendment No. 1 filed with the SEC on June 5, 2023, with respect to the Common Stock, par value $0.0001 per share (the “Common Stock”), of GreenLight Biosciences Holdings, PBC, a Delaware public benefit corporation (the “Issuer” or the “Company”). Capitalized terms used herein and not otherwise defined have the meanings assigned to such terms in the Statement. Except as otherwise provided herein, each Item of the Statement remains unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, where such information is relevant.

     

    Item 4.

    Purpose of Transaction.

    Item 4 of the Statement is hereby amended and supplemented as follows:

    Consummation of Merger

    On July 24, 2023, pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), by and among the Issuer, SW ParentCo, Inc., a Delaware corporation (“Parent”), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Issuer (the “Merger”), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent.

    Immediately prior to the effective time of the Merger, pursuant to the Merger Agreement and Contribution and Exchange Agreement, each of Kodiak III and Kodiak III-E contributed all of their respective shares of Common Stock to Parent in exchange for shares of Series A-2 Preferred Stock of Parent.

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 of the Statement is hereby amended and restated in its entirety as follows:

     

    (a)-(b)   This Amendment No. 2 is being filed on behalf of the Reporting Persons to report that, as of July 24, 2023, the Reporting Persons do not beneficially own any shares of Common Stock.
    (c)   Except as described in Item 4, during the past 60 days, none of the Reporting Persons has effected any transactions with respect to the Common Stock.
    (d)   Not applicable.
    (e)   As of July 24, 2023, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: July 26, 2023

     

    Kodiak Venture Partners III, L.P.
    By:   Kodiak Ventures Management III, L.P.
    Its:   General Partner
    By:   Kodiak Ventures Management (GP), LLC
    Its:   General Partner
    By:  

    /s/ David Furneaux

    Name:   David Furneaux
    Title:   Manager
    Kodiak III Entrepreneurs Fund, L.P.
    By:   Kodiak Ventures Management III, L.P.
    Its:   General Partner
    By:   Kodiak Ventures Management (GP), LLC
    Its:   General Partner
    By:  

    /s/ David Furneaux

    Name:   David Furneaux
    Title:   Manager
    Kodiak Ventures Management III, L.P.
    By:   Kodiak Ventures Management (GP), LLC
    Its:   General Partner
    By:  

    /s/ David Furneaux

    Name:   David Furneaux
    Title:   Manager
    Kodiak Ventures Management (GP), LLC
    By:  

    /s/ David Furneaux

    Name:   David Furneaux
    Title:   Manager
    Get the next $GRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRNA

    DatePrice TargetRatingAnalyst
    12/8/2022$4.00Buy
    Canaccord Genuity
    10/14/2022$5.50Outperform
    Credit Suisse
    More analyst ratings

    $GRNA
    Financials

    Live finance-specific insights

    See more
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GreenLight Biosciences with a new price target

      Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00

      12/8/22 9:11:51 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse initiated coverage on GreenLight Biosciences with a new price target

      Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

      10/14/22 7:27:11 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GRNA
    SEC Filings

    See more
    • GreenLight Announces Completion of Merger with Fall Line Endurance Fund

      LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r

      7/24/23 9:49:15 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

      6/3/23 8:17:00 PM ET
      $AAIC
      $EMBK
      $GRNA
      $REUN
      Real Estate Investment Trusts
      Real Estate
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 4:25:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 10:54:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/27/23 4:24:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kodiak Venture Partners Iii Lp

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:55:29 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:48:26 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Clarke Dennis A.

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:25:48 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC

      15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      8/11/23 9:00:27 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)

      8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/28/23 9:02:32 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by GreenLight Biosciences Holdings PBC

      EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/26/23 12:15:07 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care